Atsushi Sugimura

Title: Inventor Atsushi Sugimura: Innovating the Future of Biopharmaceuticals

Introduction

Atsushi Sugimura, an accomplished inventor based in Hyogo, Japan, is recognized for his significant contributions to biopharmaceutical manufacturing processes. With a total of six patents to his name, he is at the forefront of innovative methods for producing therapeutic proteins, notably human erythropoietin and alpha-galactosidase A.

Latest Patents

Among Sugimura's most notable patents is a method for the production of mutant-type human erythropoietin. This patent describes a highly efficient process utilizing transformed mammalian cells to produce the therapeutic protein. The method involves a series of purification steps, including hydrophobic column chromatography and gel filtration, ensuring a high degree of purity in the final product.

Another significant patent focuses on the production of recombinant human alpha-galactosidase A from materials contaminated with host cell proteins. This method allows for large-scale production while maintaining high purity levels. The comprehensive process includes culturing mammalian cells in a serum-free medium and several chromatography techniques, culminating in gel filtration.

Career Highlights

Atsushi Sugimura is currently affiliated with JCR Pharmaceuticals Co., Ltd., a company known for its focus on innovative biopharmaceuticals. His role within the company has allowed him to refine and implement advanced production techniques, showcasing his commitment to improving therapeutic outcomes for patients.

Collaborations

Throughout his career, Sugimura has collaborated with notable colleagues such as Kazutoshi Mihara and Atsuko Kawasaki. These collaborations have further enhanced his work, bringing diverse expertise and insights into the development of innovative biopharmaceutical processes.

Conclusion

Atsushi Sugimura exemplifies the innovative spirit that drives advancements in the biopharmaceutical industry. His patents not only contribute to the field of drug development but also highlight the importance of collaboration in achieving breakthroughs in medical science. As he continues to develop new techniques, the impact of his work on patient care and biotechnological advancements remains profound.